Trump's Vaccine Plan Faces Hurdles: Experts Cite Costs and Logistics
President Donald Trump's executive order to separate childhood vaccines faces significant financial and logistical challenges. Public health experts argue there is no scientific basis for the proposed changes, which could take years and millions of dollars to implement.
Key takeaways
- President Trump's executive order proposes separating combination vaccines like MMR into individual shots and spacing them out.
- Public health experts state there is no scientific basis for this change and consider it poor public health policy.
- Implementing the order would require drugmakers to revive old vaccine formulations, build new plants, and undergo extensive FDA review, potentially taking years and millions of dollars.
- Current U.S. standards use combination vaccines, which studies show improve full protection rates for children before school entry.
An executive order from President Donald Trump aims to alter the delivery of childhood vaccinations in the United States, proposing the separation of combination vaccines, such as the measles, mumps, and rubella (MMR) shot, into individual injections. The order also suggests spacing out these vaccinations whenever feasible.
What Happened
The presidential directive calls for a significant overhaul of vaccine administration. Drug manufacturers would be required to reintroduce individual vaccines that have not been widely used in the U.S. for decades. Additionally, they would need to establish new manufacturing facilities to produce millions more doses than are currently available. For parents, this would mean more frequent doctor's visits, potentially straining pediatricians' schedules and increasing costs associated with medical supplies.
Background
Combination vaccines, like the MMR shot, have been the standard in the U.S. since the 1970s. Studies indicate that these combination vaccines increase the likelihood of children receiving full protection against infectious diseases before starting school. Individual vaccine doses for measles and related illnesses are typically used in lower-income countries that cannot afford the combination MMR vaccine.
Key Facts
- President Donald Trump issued an executive order to separate childhood vaccines, including the MMR vaccine.
- The order suggests spacing out vaccinations and requiring drugmakers to revive decades-old individual vaccine formulations.
- Currently, no individual vaccines for measles, mumps, or rubella are available in the U.S.; only combination shots are approved by the FDA.
- Pharmaceutical scientists and former regulators estimate that implementing these changes could take years and cost tens of millions of dollars for new studies and manufacturing facilities.
- Designing and building new vaccine plants can take approximately five years, followed by FDA review and licensing for each individual vaccine.
- Merck and GSK, major vaccine suppliers, stated they stand by the safety and effectiveness of their current combination products.
Why It Matters
Public health experts have criticized the plan, stating there is no scientific justification for altering the current vaccination schedule. Dr. Anna Durbin of the Johns Hopkins Bloomberg School of Public Health described the policy as "very bad public health policy," emphasizing that such changes should only be implemented if there is a valid reason, which she argues is absent in this case. The unbundling and spacing of vaccines could potentially compromise public health by reducing vaccination rates, as combination shots are shown to increase adherence.
What Happens Next
Federal officials are tasked with developing plans within 90 days for separating the MMR shot and spacing out other vaccines. However, experts caution that the actual implementation could extend over several years due to the extensive regulatory and manufacturing hurdles involved, including potential requirements for new large-scale clinical studies to demonstrate the efficacy and safety of individual vaccines and their manufacturing processes.
Sources reviewed
Project Chintan independently synthesized and analyzed information cross-checked across the sources listed above.
Related stories
Measles Cases Rise in Pennsylvania Amid State Outbreak
FDA Approves Moderna's mRNA Flu Vaccine for Adults 50+
Supreme Court Criticizes FSSAI Over Delayed Food Warning Labels
